Fulcrum Therapeutics Stock Options Expiring on 16th of January 2026
| FULC Stock | USD 3.77 0.11 2.84% |
Fulcrum Therapeutics' latest option contracts expiring on 2026-01-16 are carrying combined implied volatility of 1.29 with a put-to-call open interest ratio of 0.0 over 3 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2026-01-16.
Fulcrum Therapeutics' stock options are financial instruments that give investors the right to buy or sell shares of Fulcrum Therapeutics common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Fulcrum stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Fulcrum Therapeutics' stock price goes up or down, the stock options follow.
At present, Fulcrum Therapeutics' Stock Based Compensation To Revenue is projected to increase slightly based on the last few years of reporting. Fulcrum Therapeutics In The Money Call Balance
When Fulcrum Therapeutics' strike price is surpassing the current stock price, the option contract against Fulcrum Therapeutics stock is said to be in the money. When it comes to buying Fulcrum Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Fulcrum Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Fulcrum Current Options Market Mood
Fulcrum Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Fulcrum Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Volume
Unfortunately, most Fulcrum Therapeutics' options investors are not very successful. Fulcrum Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Fulcrum contract
Base on the Rule 16, the options market is currently suggesting that Fulcrum Therapeutics will have an average daily up or down price movement of about 0.0806% per day over the life of the 2026-01-16 option contract. With Fulcrum Therapeutics trading at USD 3.77, that is roughly USD 0.00304. If you think that the market is fully incorporating Fulcrum Therapeutics' daily price movement you should consider buying Fulcrum Therapeutics options at the current volatility level of 1.29%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Fulcrum |
Fulcrum Therapeutics Option Chain
When Fulcrum Therapeutics' strike price is surpassing the current stock price, the option contract against Fulcrum Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Fulcrum Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Fulcrum. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Fulcrum. It also shows strike prices and maturity days for a Fulcrum Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Expiration | Current Spread | Last Price | |||
Call | FULC Option Call 16-01-2026 3 | 10 | 2026-01-16 | 0.05 - 5.0 | 1.6 | In |
Call | FULC Option Call 16-01-2026 7 | 5 | 2026-01-16 | 0.05 - 5.0 | 0.75 | Out |
Put | FULC Option Put 16-01-2026 7 | 0 | 2026-01-16 | 0.0 - 0.0 | 4.0 | In |
Fulcrum Total Stockholder Equity
Total Stockholder Equity |
|
Fulcrum Therapeutics Corporate Management
| Rudolf MD | Founder | Profile | |
| CPA CMA | Chief Officer | Profile | |
| Jeffrey Jacobs | Chief Officer | Profile | |
| Mel Hayes | Executive Experience | Profile | |
| Paul Bruno | Senior Development | Profile | |
| Bryan Stuart | CEO Pres | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 1.317 | Quarterly Revenue Growth 89.909 | Return On Assets (0.07) | Return On Equity (0.07) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.